- COVID-19 infection increases risk of a range of neurological diseases,
- Cancer patients eating ice cream can reduce this side effect of chemotherapy
- Gut microbes may become a new therapy for depression and anxiety
- The risk of Alzheimer’s disease increases by 50-80% within a year after COVID-19 infection
- Hong Kong will launch monkeypox vaccination for high-risk groups in October
- Ebola (Sudan strain) outbreak in Uganda
Hepatitis B new drug ATI-2173: Research Data Soon
Hepatitis B new drug ATI-2173: Research Data Soon. Hepatitis B new drug ATI-2173, clinical phase I, will announce research data soon.
Antios Therapeutics, a biopharmaceutical company, mainly focuses on the development of innovative therapeutic drugs for treatment and viral diseases. At present, the company is currently in phase I of the human clinical phase of the new hepatitis B drug ATI-2173, which aims to provide a combined treatment plan for chronic hepatitis B patients. On December 1, 2020, the company announced the appointment of Gregory T. Mayes as CEO and Director, and introduced in the announcement: ATI-2173 will soon announce the results of the Phase I study in healthy volunteers and HBV-infected subjects ( (See the picture below from: Antios announcement by biopharmaceutical company).
Hepatitis B new drug ATI-2173, clinical phase I, will announce research data soon
The announcement is as follows:
Biopharmaceutical company Antios Therapeutics has appointed Gregory T. Mayes as CEO. The former CEO and co-founder of Antios, Dr. Abel De La Rosa, was appointed as the chairman of the board. Mayes, will continue to lead the development of the new hepatitis B drug ATI-2173, which serves as the backbone of a potential hepatitis B treatment plan. Gregory T. Mayes is the successor of Dr. Abel De La Rosa. He co-founded Antios in 2018 and has served as CEO and Director since the company was founded.
While Dr. De La Rosa will retire from his full-time position, he will continue to serve as an advisor to Antios and serve as the chairman of its board of directors. ATI-2173, it is a new type of liver-targeting molecule designed to deliver 5′-monophosphate of clevidine. The active 5′-triphosphate of this l-nucleoside has unique antiviral properties, as a non-competitive, non-chain terminating HBV polymerase inhibitor. By selectively delivering 5′-monophosphate to the liver while retaining the unique anti-hbv activity of active 5′-triphosphate, ATI-2173 may become an integral part of the treatment package for chronic hepatitis B.
The comment from Dr. De La Rosa:
“On behalf of the board of directors, we are very happy that Greg has joined Antios as our new CEO and led the company to the next stage of development. Greg is an accomplished biopharmaceutical company executive with an outstanding track record in establishing start-up companies and managing mature organizations. He has led the company’s early and late clinical development projects, as well as various commercial activities.
At present, our main clinical candidate drug, ATI-2173, is approaching an important turning point in its development. We will soon announce the results of our Phase 1 human clinical study in healthy volunteers and HBV-infected subjects. It will be launched in early 2021. Start our second phase of the project. I used to lead Antios from pre-clinical development to a well-capitalized biopharmaceutical company in the clinical stage. I think this is a good time for leadership to change.
I am sure that we are ready to continue to succeed, and I am confident that Antios will flourish under Greg’s leadership. As the co-inventor of ATI-2173, I am full of confidence in its success and look forward to continuing to actively participate, whether it is as the chairman of the board of directors or as a new role as a senior scientific and strategic advisor.”
The following is the original comment from the newly appointed CEO and director Gregory T. Mayes:
“I am very grateful for the opportunity given to me by the board of directors. In ATI-2173, we have a promising clinical drug candidate and convincing scientific principles, positioning it as a potential pillar of a functional cure for chronic hepatitis B treatment. , An important unmet need. I look forward to leading its continued clinical development and bringing more opportunities to Antios.”
(The above about the upcoming announcement of the new hepatitis B drug ATI-2173, the first phase of human clinical trials in healthy volunteers and HBV infected subjects, published in the announcement of Antios Therapeutics on Tuesday, December 1, 2020)
(source:chinanet, reference only)